Global law firm White & Case LLP has advised Biosynex SA, a market-leading designer and distributor of rapid diagnostic tests, on its entry into a definitive merger agreement with Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, under which Biosynex will acquire Chembio by an all-cash tender offer for US$.45 per share.
The acquisition combines two leading rapid diagnostic test companies. Upon closing of the transaction, Biosynex will operate Chembio and its 100 percent owned German, Brazilian and Malaysian subsidiaries as a wholly owned group.

Based in France, Biosynex, designs, manufactures and distributes rapid diagnostic tests as well as diagnostic equipment for healthcare professionals and the general public, aiming to improve patient care through quick results and ease of use. Biosynex provides pharmacies and professional healthcare settings with a diversified portfolio of rapid tests covering different market segments including infectious disease and women’s health tests, point-of-care devices and molecular diagnostics systems.

Reference: https://www.whitecase.com/news/press-release/white-case-advises-biosynex-merger-agreement-chembio-diagnostics-inchttps://www.whitecase.com/news/press-release/white-case-advises-biosynex-merger-agreement-chembio-diagnostics-inc